Maxim Group Keeps Their Buy Rating on Moleculin Biotech (MBRX)


In a report released today, Jason McCarthy from Maxim Group maintained a Buy rating on Moleculin Biotech (MBRX), with a price target of $3. The company’s shares opened today at $1.27.

McCarthy commented:

“Following last month’s clearance to begin its European clinical trial of WP1220 (STAT3 inhibitor) in the topical treatment of cutaneous T-cell lymphoma (CTCL), Moleculin announced that the first two patients have been enrolled.”

According to TipRanks.com, McCarthy is a 1-star analyst with an average return of -0.3% and a 36.6% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as Actinium Pharmaceuticals, Inovio Pharmaceuticals, and Vertex Pharmaceuticals.

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Moleculin Biotech with a $3 average price target.

See today’s analyst top recommended stocks >>

Based on Moleculin Biotech’s latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $2.79 million. In comparison, last year the company had a GAAP net loss of $3.19 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Moleculin Biotech, Inc. is a clinical stage pharmaceutical company, which focuses on the development of oncology drug candidates. Its Annamycin product candidate helps in the treatment of relapsed or refractory acute myeloid leukemia.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts